afternoon, you, everyone. joining Thank for XXXX today Leiv, quarter us second good and for you Thank business update. our
therapies. X, as patients, of Cancer presentation included three failed the ciforadenant, of in fixed-dose as combination our and including pathway development presentation the XXXX. oral leader anticipated daily. Investigator an was adenosine data Center. a and meeting, at from by of immuno-oncology in doses of oral in refractory at Director received During days Principal key kilogram of kilogram per intravenously prior four patients University of X will other X, disease These XX CPI-XXX, total patients of the the XXX of with Dr. data milligrams on the had highlights June. all ASCO, ASCO the X, given presentation along remainder recap a quarter, programs, milestones treatment a the a We X, development initial of medicines. we second-generation at who highlighted every of Jason ASCO a an plus Pittsburgh in position monotherapy reinforcing today's update days presentation continued The all Cancer the twice XXX trial milligrams XX at milligrams call, advanced every per XX positive CPI-XXX clinical The Center, presented X, the On an received from had Immunotherapeutic Luke, our therapeutics, of and the Hillman median trial based X programs, patients in Medical data advancing from of of by XX who our CPI-XXX and very for a I development had initial clinical our clinical provide the the of Center XX
its it CPI-XXX We anti-CDXX developing are novel, created of immunomodulatory is antibody. this unique antibody possesses kind, and first a properties. because
We pleased results targeting of selective they at active presented ASCO set expected be we blockade are as immune the to The out is immunologically and adenosine with XXX, very combination and confirm to create synergistic. stimulation with antibody what an CDXX.
the from presentation Let a me give at few takeaways ASCO.
patients we CDXX is induced trafficking emphasize lymphoid aware sensitized why peripheral cells. And of to happens. immune Treatment the adenosine exquisite the CDXX a stimulation the and targeting activity, of positive via of antigen want CDXX its Other antibody. immunologic to that dual of blocking cells, a data support independent immune do antigens B-cell new laboratory small It of described adenosine. antibody course, to immune lymph antibodies More found cells of molecule markers and our also also production the we effects expression immune the of on treated with Because has other antibody. the are associated activation these where of protein approach the interacts CDXX tumor presenting of activation And to specifically, important? from co-stimulatory is results of these agent, trafficking of both in CDXX or to have suggests lymphocyte blocks leads production. of but an immunotherapeutic First, are clinical the been site immunosuppressive tissues. CPI-XXX binds its evidence activation. molecule, properties. nodes, cells supports is in on the that XXX specific XXX that not a selectivity system action consistent collected activation enzymatic and namely inhibition these CDXX site adenosine. activated cells effects patients. become to regional the with exhibited that's process of the this in any cells regard. with Together, that, This to with tissue, to independent is and our lymphoid that its that peripheral on I agonist the
companies that have inhibitors such I impossible, enzymatic very CDXX described. Some will unlikely, these of molecule that actually small developing immunomodulatory CDX just effects agents activity, are is -- it
the milligrams occupancy Second, shown per a as achieved with early monotherapy are our dose. included to and This In the -- achieve of trend in X we to longer short, were of refractory of when very Doses milligrams sites administered given advanced disease -- in toward X results receiving in control CPI-XXX kilogram disease with was with demonstrated control CDXX when when therapy patients patients it kilogram patients per tumor higher, doses ciforadenant. optimum of dose-dependent per kilogram and antigen and saturation CDXX and in a combination higher initial doses in sustained on on disease the enhance in was combination a lymphocytes XX appeared and blood the control. zeroing milligrams biopsies. peripheral disease
see particular, very were cancer. cancer previous of signs and we regression occurring see we of These very to pleased were with resistant Third, activity signs treatments. control to patients prostate and in in cancers. cell early In tumor patients advanced renal
tolerated as dose-limiting We levels also far. CPI-XXX safety observed with toxicities at was dose all a so reported no well positive profile
Day confirmed and scientists presentation with our for to of delighted of was by presentation ASCO's ASCO are The the sessions. from the data of one importance of selection clinicians. response We our the the Highlight
understanding the be a of of handful discoveries that highlight, these Day leading a are sessions, way attendees our papers Dr. highlighted findings approach with to emphasizing coming the meeting. of to ASCO In and may highlight of themes only to with provide monotherapy researcher single-agent very and with to be Disis, Mary the important not of those out oncology clinical made enhance Editor-in-Chief for a key keep we have that informed selected and the because University JAMA an For clinical Disis was development, about are Washington, biomarkers pharmacodynamic on activity familiar they results. confirm and the Dr. by efficient utilizing they popular the to from most presentation The Oncology. been session, starting the our
ASCO, a hosted review Meeting Investor Analyst the well-attended data. also Dr. Luke We and XXX to during featuring
our a had encourage this listen to I replay, listen would chance on to to to have you available presentation, website. If the which is not you
CPI-XXX, XXX our We immunobiology I/Ib update and and combination our very for presentation follow-up at and ASCO, with combination on advanced date, pleased arms: agent in we to at in our study, the trends have two more arms. We from continue provide at focus increased Single SITC trial more the reported are enroll an and interest To study which ASCO first patients, stimulated in ciforadenant. Phase been the cancer patients with ciforadenant November with the monotherapy meeting with a with enrolling of has seeing clinical we continuation our a plan that now both is to in longer well.
an would adenosine patients a I in receiving exhibited across is PK ciforadenant, receptor of that as more that drug's failed a our have therapies receptor. than AXA antitumor It activity in and atezolizumab three the with like antagonist, strong to development median date. antagonist combination monotherapy AXA and the molecule the and patients has demonstrated treatment safety, in PD to prior now drug most with profile. of the small Ciforadenant landscape discuss XXX advanced candidate is
disease Some months. XX durable patients to of our control responses out and have experienced over now
Some patients therapy X.X excess of years. on in have been
advanced This most in combination enroll focused recently Ib/II has evaluating our patients in ciforadenant cancer, need. with continue been to a is renal refractory which significant cell Phase We on patients trial atezolizumab. clinical with study unmet
Phase AXA that prostate of cancer responses AstraZeneca also receiving call, presented inhibitor, our oral QX patients including cancer. noted patients in receptor I prostate in patients seen also we cancer are We we monotherapy. enrolling for showing in data their and signs On prostate efficacy that activity with have
its treated Adenosine of As future we both a metastatic predictive with single prostate going combination XX studies. for CPI-XXX. patients we in with prostate agent or protocols, ciforadenant a castration-resistant deepen about use experience with to are our to To part as with We for as ciforadenant CPI-XXX date, for have cancer combination Signature testing forward. evaluate cancer plan in for patients marker and atezolizumab the with these
broaden to adenosine we the receptor AXB our continue inhibitor Related the advance selective study goal studies. to pathway with adenosine to through pipeline, and and preclinical our
the it Our literature effects meaningful scientists reported something fibrosis plan immune system, and related in that the This receptor been inhibiting activity have AXB research we on other shown has does exploring. by to does continue is on and effects but have not processes. has other the
one or we the by to and with AXA we combinations reported addition a is with dual drugs persuasive AXB do for and either immunotherapy, in receptors dual drugs of AXB AXA group, simultaneous there that synthesized. not have evidence inhibitor explore selected believe Although of
CPI-XXX cytotoxic believe directly Phase are cutaneous tumors. Outside of I/Ib T-cell a to in others. patients for inhibitor ITK pathway, has may molecule by lymphomas lymphomas, T-cell and potential study be the small T-cell to could the benefit for and we of of lymphoma enrolling and called our adenosine We solid lymphoma, with peripheral what our to also THX CPI-XXX, the immune immune system response, the enhancement increasing lead provide T-cell lymphomas is which therapeutic including
very indicates a autoimmunity. Some examine be this of attractive may our also candidate to that research drug in
As South scientific myself, team treated at a approved on similar CPI-XXX strategy reminder, as was now now of the BTK Korea. first inhibitors, the the BTK and during targeting members open development of the study such types in several a Corvus, based United CPI-XXX We including quarter, of lymphomas. of the and is is for the our the second ibrutinib, first in treatment that led and ibrutinib, development the patient inhibitor, to of the study States, B-cell which Australia of
far, well with pleased are been findings. and the So we has and PD tolerated, CPI-XXX PK
late We in presented data be or early clinical XXXX XXXX. expect early to
is positioned Corvus in candidates three unique In summary, believe we well the to with clinic. continue
adenosine unique We on are at based latest of that data is dual antibodies blockade. CPI-XXX mechanism presented immunomodulation the action, and its among with CDXX encouraged demonstrating ASCO,
signs of data at and forward the antitumor presenting CPI-XXX the study additional SITC We in this early to in more November. later mature are activity seeing year positive look meeting
appear Corvus, with specificity pharmaceutical and complete high for are combination And be blockade owned attractive which properties, including receptor Ciforadenant continues importantly, and therapy. demonstrate to ciforadenant to wholly AXA. a CPI-XXX, potential as complementary by attractive
our at our future assets, business clinic, but the we medical majority programs with our calls. Outside look be work. updates three our of on in are We our also forward progress of in pipeline the to update our advancing focus upcoming meetings and clinical pipeline to on providing continues
and data remind reception. about where everyone me SITC hosting clinical anticipate November, in we Let more investor an presenting
the I turn will to now over operator question-and-answer a for the Operator? session. call
